MDM2 and soft tissue sarcoma: MDM2 amplification emerged as an oncogenic pathway in several malignances, but it is mostly represented in soft tissue sarcomas [14,15,16,17] where, differently from other tumors, MDM2 amplification and p53 mutation are mutually exclusive [18,19,20,21].